In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other pharma stocks. Healthcare takes the concept of 'defensive' further than almost any ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other pharma stocks. Healthcare takes the concept of ‘defensive’ further than almost ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall ...

Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

The company maintains a moderate level of debt relative to its equity with a debt-to-equity ratio of 2.19, suggesting a relatively balanced financial structure. Key Takeaways For Eli Lilly in the ...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...

Eli Lilly’s (NYSE: LLY) market isn’t out of the weeds yet but will rebound strongly in 2025. The Q3 results failed to spark a ...